Neurotech Solutions
AI-based Technology for Diagnosing ADHD
Startup Mature Health Tech & Life Sciences Est. 2008
Total Raised
$3.55M
Mature
Last Round
$54.26K
3 rounds
Investors
3
3 public
Team
6
11-50 employees
Confidence
91/100
News
3
articles
Patents
1
About
Neurotech solutions is a digital health company focused on eliminating undiagnosed ADHD. The companys mission is to help every person with ADHD lead a better life and fulfill their potential. Neurotech Solutions core technology is a cloud-based, AI-driven online test that looks and feels like a game. The technology was first implemented in a clinical product called MOXO d-CPT, a decision-support tool for the diagnosis of ADHD. Using MOXO d-CPT, a healthcare professional can obtain objective, standardized, comparative results about a patients attentional difficulties in just 14 to 18 minutes. More than 500,000 MOXO tests have been performed to date in over 20 countries. During the COVID-19 pandemic, the company released a home version of MOXO to enable a full remote and objective diagnosis of ADHD. The companys core technology was also implemented in an educational product called AXON-School. Intended for all K-12 children, the product objectively highlights children with attentional difficulties and suggests educational strategies for personalized learning. Neurotech Solutions opened a subsidiary in Guangzhou, China, in 2021.
Classification
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Core Technology
Data StorageCloudArtificial Intelligence
Target Customer
EducationK12 EducationHealthcare & Life SciencesHealthcareProvidersConsumersDemographics & FamilyChildren
Business Model
B2B2CB2B
Tags
childrendoctorslearning-disabilitiesneurologydigital-healthcareweb-applicatione-healthdiagnosticsdecision-makingschoolsedtechk-12real-timehealthcare-providersadhdmhealthmedical-deviceshome-caremedical-technologiesnon-invasiveclinicsdata-analyticsdecision-supporttreatmentsartificial-intelligencemonitoring
Funding & Events
Mar 2018
Undisclosed Round $3.5M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
Aug 2019
Non-equity $54.26K
EU Horizon 2020
Undisclosed Round Undisclosed
Noaber, Impact First Investments
News (3)
Jul 9, 2020 · cordis.europa.eu
Mobile device for ADHD diagnosis and support MOXO-Mobile Phase-1 Project Results in brief H2020 CORDIS European Commission
Mar 14, 2018 · www.linkedin.com
growth-positive
Neurotech-Solutions Secures $3.5 Million to Fuel Aggressive Growth of its ADHD screening and diagnosis business in China.
InvestmentPartners
Jun 18, 2015 · www.israel21c.org
growth-positive
Customizing ADHD evaluation
Customers
Details
Product Stage
Released
Employees
11-50
Exact Count
15
District
Center District
Founded
2008
Registrar
514105287
Crunchbase
neurotech-solutions
Locations
Pinkas Street 66, Tel Aviv-Yafo, Israel
Guangzhou, Guangdong, China
Links
Website
LinkedIn
Facebook
Admin
Last Update
Sep 28, 2024
Verified by
Yanina Wainscheinker
Missing
markets, not claimed
Team (6)
Gil Heled
CTO
Amit Foox
VP Sales
Roni Bochman-Ronen
Marketing Director
Noa Kezurer
Product Director
Aviram Salomon
Product Director
Megi Franko
HR, Administration Manager
Internal
Created by
Sophie Pollock (pollos@blair.edu)
Created
2014-06-24T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)